Summary
| Name | SRSF2View Modifications |
| Full Name | Serine/arginine-rich splicing factor 2 |
| Synonyms | Protein PR264, Splicing component, 35 kDa, Splicing factor SC35, SC-35, Splicing factor, arginine/serine-rich 2 | SFRS2 |
| Primary ID | Q01130 |
| Links | - - ![]() |
| Type | protein |
| Relations | 5 |
| Pathways | Acute Myeloid Leukemia, AML1-ETO in AML, IDH-TET in AML |
| Function | Necessary for the splicing of pre-mRNA. It is required for formation of the earliest ATP-dependent splicing complex and interacts with spliceosomal components bound to both the 5'- and 3'-splice sites during spliceosome assembly. It also is required for ATP-dependent interactions of both U1 and U2 snRNPs with pre-mRNA. Interacts with other spliceosomal components, via the RS domains, to form a bridge between the 5'- and 3'-splice site binding components, U1 snRNP and U2AF. Binds to purine-rich RNA sequences, either 5'-AGSAGAGTA-3' (S=C or G) or 5'-GTTCGAGTA-3'. Can bind to beta-globin mRNA and commit it to the splicing pathway. The phosphorylated form (by SRPK2) is required for cellular apoptosis in response to cisplatin treatment. |
Viewer
Search Tools
Refine search:
- by mechanism
- by effect
- by organism:
- by tissue:
- by cell-line
Modifications Tables
Relations
| Regulator | Mechanism | target | score ℹ | |
|---|---|---|---|---|
| + | KAT5 | down-regulates
acetylation
|
SRSF2 | 0.468 |
| Publications: | 1 | Organism: | Homo Sapiens | |
| Pathways: | Acute Myeloid Leukemia, IDH-TET in AML | |||
| + | HDAC6 | up-regulates
deacetylation
|
SRSF2 | 0.356 |
| Publications: | 1 | Organism: | Homo Sapiens | |
| + | DYRK1A | down-regulates activity
phosphorylation
|
SRSF2 | 0.411 |
| Publications: | 1 | Organism: | Homo Sapiens | |
| + | SRP54 | up-regulates activity
binding
|
SRSF2 | 0.343 |
| Publications: | 1 | Organism: | In Vitro | |
| + | SRSF2 | up-regulates quantity by expression
transcriptional regulation
|
MDM2 | 0.28 |
| Publications: | 1 | Organism: | Homo Sapiens | |
| Pathways: | Acute Myeloid Leukemia, AML1-ETO in AML, IDH-TET in AML | |||
4.0
SRSF2


acetylation
deacetylation